as 06-06-2025 1:41pm EST
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Founded: | 1997 | Country: | Israel |
Employees: | N/A | City: | N/A |
Market Cap: | 21.1M | IPO Year: | 2018 |
Target Price: | $40.00 | AVG Volume (30 days): | 17.2K |
Analyst Decision: | Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -4.68 | EPS Growth: | N/A |
52 Week Low/High: | $3.34 - $16.50 | Next Earning Date: | 05-23-2025 |
Revenue: | $12,103,000 | Revenue Growth: | 603.66% |
Revenue Growth (this year): | -31.93% | Revenue Growth (next year): | 31.17% |
SLGL Breaking Stock News: Dive into SLGL Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
Zacks
3 months ago
Simply Wall St.
4 months ago
MT Newswires
5 months ago
The information presented on this page, "SLGL Sol-Gel Technologies Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.